The androgen receptor (AR) plays an important role in the initiation and progression of prostate cancer (CaP). Preliminary data show that expression of microRNA Let-7c is downregulated in CaP cells and tissues compared to benign prostate. Let-7c suppresses AR expression and overexpression of let-7c reduces AR activity, suggesting that let-7c may contribute to AR modulation in CaP cells. Additional studies suggest that let-7c- mediated AR suppression is via c-myc, an AR activator that is consistently overexpressed in prostate cancer. In addition, let-7c decreases the growth of CaP cells in vitro and in vivo. Furthermore, analysis of specimens from human prostate indicates a reverse correlation between Let-7c and AR expression. These data suggest that Let-7c plays an important role in regulating AR signaling and the development and progression of CaP. This proposal is aimed at understanding a novel microRNA (miRNA) let-7c-myc- mediated AR signaling pathway and the interaction between them.
Three specific aims are proposed to this study.
Aim 1 is to determine the effect of let-7c on cell growth and androgen responsiveness. We will knockdown Let-7c expression in androgen- responsive human prostate cancer cell lines, and assess the effects of such downregulation on the growth and on the androgen responsiveness of the cells. Conversely, we will overexpress Let-7c in castration-resistant prostate cancer cells to determine whether it can suppress cell growth and cause a reversal to an androgen- dependent state.
Aim 2 is to characterize let-7c as a modulator of AR and c-myc. We will characterize the potential mechanisms of let-7c-mediated AR suppression and the role of c-myc in this process. We will study whether let-7c suppresses AR expression and its transcriptional functions, and whether it is via suppression of c-myc. We will determine whether let-7c directly targets c-myc RNA and whether c-myc recruitment to AR promoter is affected. Furthermore, we will explore how let-7c expression is regulated in prostate cancer cells.
Aim 3 is to determine the relationship between let-7c, AR, and c- myc expression and prostate cancer progression. We will test the relationship of Let-7c, AR and c-myc in clinical prostate cancer specimens, and determine whether the levels of these three important molecules correlate with disease progression and castration resistance in specimens from patients with prostate cancer. If a novel pathway that connects AR, c-myc, and microRNAs is identified, it will gain a better understanding of the molecular mechanisms leading to prostate cancer development and progression.

Public Health Relevance

Androgen receptor signaling plays critical roles in prostate development and cancer progression. We propose to explore the roles of microRNA let-7c in androgen receptor signaling and prostate cancer progression. Understanding the mechanisms of androgen receptor regulation and identification of molecular targets would greatly benefit to patients with prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA168601-02
Application #
8634069
Study Section
Special Emphasis Panel ()
Program Officer
Sathyamoorthy, Neeraja
Project Start
2013-04-01
Project End
2018-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
2
Fiscal Year
2014
Total Cost
$310,892
Indirect Cost
$103,392
Name
University of California Davis
Department
Urology
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Tummala, Ramakumar; Nadiminty, Nagalakshmi; Lou, Wei et al. (2016) Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. Prostate 76:445-55
Liu, Chengfei; Armstrong, Cameron; Zhu, Yezi et al. (2016) Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget 7:32210-20
Zhu, Yezi; Liu, Chengfei; Armstrong, Cameron et al. (2015) Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. Clin Cancer Res 21:4133-42
Nadiminty, Nagalakshmi; Tummala, Ramakumar; Liu, Chengfei et al. (2015) NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Mol Cancer Ther 14:1884-95
Liu, Chengfei; Lou, Wei; Armstrong, Cameron et al. (2015) Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate 75:1341-53
Liu, Chengfei; Lou, Wei; Zhu, Yezi et al. (2015) Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res 75:1413-22
Liu, Chengfei; Zhu, Yezi; Lou, Wei et al. (2014) Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate 74:201-9
Zhu, Yezi; Liu, Chengfei; Cui, Yuanyuan et al. (2014) Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). Prostate 74:1086-94
Liu, Chengfei; Lou, Wei; Zhu, Yezi et al. (2014) Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res 20:3198-210
Cui, Yuanyuan; Nadiminty, Nagalakshmi; Liu, Chengfei et al. (2014) Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer 21:435-42

Showing the most recent 10 out of 13 publications